Italy seeks 1.2 bn euros in anti-trust damages from Roche, Novartis

Italy's health ministry is seeking 1.2 billion euros ($1.6 million) in compensation from Swiss pharma giants Novartis and Roche for the manipulation of sales of a cheap drug used to treat eye problems, Italian media reported Wednesday.

The ministry's move came after Italy's antitrust body fined the two firms 182.5 million euros over their "illicit deal to prevent the use of a very cheap drug, Avastin, in treating" sight problems.

The antitrust body said the two pharma giants had colluded with the aim of boosting the sales of a more expensive product, Lucentis. It also claimed that they steered health services and doctors away from Avastin by describing it as more dangerous.

Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as .

Novartis has rejected the anti-competition accusations and has said it would appeal against the fine.

add to favorites email to friend print save as pdf

Related Stories

Novartis tries to make UK hospitals use $1000 drug

Apr 24, 2012

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

FDA warns of another compounding pharmacy recall

Mar 20, 2013

(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Japan prosecutors raid Novartis over drug ad scandal

Feb 19, 2014

Japanese prosecutors on Wednesday raided the offices of the local arm of Swiss pharmaceutical giant Novartis over alleged exaggerated advertising for a popular blood-pressure drug, local media said.

Recommended for you

Novartis Japan admits concealing drug side effects

4 hours ago

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments